Phase 1 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 19 years or older
- People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, confirmed by a biopsy
- People with head and neck cancer at any stage and in any location within the head and neck area, including those whose cancer has come back or who have developed a new cancer in that area
- People whose scans (a type of nuclear imaging scan called FDG-PET/CT, or a CT scan) show signs of cancer spread that need further investigation, or a main tumour with suspicious lymph nodes, before surgery
- People whose blood test results meet certain minimums for haemoglobin (a measure of red blood cells), white blood cells, and platelets (cells that help blood clot)
- People whose kidney function blood test result falls within an acceptable range
Who may not be able to join:
- People who have had a heart attack, stroke, uncontrolled heart failure, significant liver disease, or unstable chest pain within the 6 months before enrolling
- People who have previously had a serious reaction during an infusion of a monoclonal antibody (a type of targeted therapy given through a drip)
- People who are pregnant or breastfeeding
- People whose magnesium or potassium blood levels are below the normal range used by the treating institution
- People who are currently taking certain heart rhythm medications, specifically those in the class IA group (such as quinidine or procainamide) or class III group (such as dofetilide, amiodarone, or sotalol) (confirm with trial site if unsure which category applies)
- People who have a history of, or signs of, scarring or inflammation in the lungs (conditions known as interstitial pneumonitis or pulmonary fibrosis)
- People with severe kidney disease or a complete absence of urine production
- People who are known to have an allergy or sensitivity to a medication called deferoxamine or any of its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Topf, MD, Vanderbilt University/Ingram Cancer Center
Phone: 615-936-2807
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity of zirconium Zr 89 panitumumab (89Zr-panitumumab; Specificity of 89Zr-panitumumab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.